Phibro Animal Health (PAHC) director sells $1.88 million in stock

Director Jack Bendheim and BFI Co., LLC, a ten percent owner, sold a combined total of 32,043 shares of Phibro Animal Health Corp (NASDAQ:PAHC) Class A Common Stock for approximately $1.88 million. The sales occurred on November 7 and November 10, 2025, with prices ranging from $42.8554 to $46.3558. The stock is currently trading near its 52-week high of $46.42, having delivered an impressive 121% return year-to-date and 83% over the past year, according to InvestingPro data.

The sales were executed by BFI Co., LLC, pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025. On November 7, BFI Co., LLC sold 3,520 shares at a weighted average price of $42.8554, with prices ranging from $42.61 to $43.195. On November 10, the entity sold an additional 4,124 shares at a weighted average price of $44.0046, with prices ranging from $43.31 to $44.28; 14,086 shares at a weighted average price of $44.9070, with prices ranging from $44.31 to $45.26; 19,773 shares at a weighted average price of $45.8149, with prices ranging from $45.33 to $46.32; and 320 shares at a weighted average price of $46.3558, with prices ranging from $46.355 to $46.36.

Following these transactions, BFI Co., LLC indirectly holds 20,577 shares. Jack Bendheim, who has voting and dispositive power over BFI, may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim also directly holds 16,840 shares.The insider selling comes as Phibro trades at a P/E ratio of 27.7 and a price-to-book ratio of 6.0, with a market capitalization of $1.86 billion. Despite the selling activity, the company maintains strong financial health with a current ratio of 3.09, indicating ample liquidity. InvestingPro analysis shows the company is expected to grow its net income this year, with two analysts recently revising earnings estimates upward for the upcoming period. For deeper insights on PAHC and 1,400+ other stocks, check out the comprehensive Pro Research Reports available on InvestingPro.

In other recent news, Phibro Animal Health Corporation reported robust first-quarter results for fiscal year 2026. The company posted earnings per share of $0.73, significantly surpassing the analyst forecast of $0.60. Additionally, Phibro’s revenue reached $363.9 million, exceeding expectations of $345.44 million. These results indicate a strong start to the fiscal year and have been well-received by investors. In related developments, BofA Securities raised its price target for Phibro Animal Health to $32 from $27. Despite the increase, the firm maintained an Underperform rating on the stock. The revised price target reflects stronger demand for protein and improved profitability in the Livestock sector, along with reduced costs for feed and grain inputs. This adjustment underscores Phibro’s strengthened position within the industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.